Review Article

Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors

Author(s): Ping Duan, Lili Fan, Quansheng Gao, Bal Mukunda Silwal, Mulan Ren, Yang Shen* and Wanglei Qu*

Volume 18, Issue 10, 2017

Page: [1171 - 1178] Pages: 8

DOI: 10.2174/1389450118666170329095807

Price: $65


Specific blocking of interactions between ligands and receptors along the angiogenic pathways represents an effective approach for enhancing the efficacy as well as reducing adverse effects of chemotherapy. Over the past decade, there was a rapid progression in the application of this therapeutic strategy in cancer treatment. Anti-angiogenic therapy is the most promising targeted therapy for ovarian cancer. The addition of bevacizumab to conventional chemotherapy, either in the first-line setting or at disease relapse, may improve overall survival (OS) of ovarian cancer patients, at least in a subset of patients with poor prognosis. In this article, we summarize published data on the major agents used for anti-angiogenic therapy in ovarian cancers. We will review the molecular mechanisms, results of clinical trial of existing agents and describe the development of new agents. The limitations and side effects of angiogenesis inhibitor are also discussed.

Keywords: Ovarian cancer, molecular targeting, anti-angiogenic agents, angiogenesis, cancer therapy, inhibitor.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy